Financials data is unavailable for this security.
View more
Year on year Alnylam Pharmaceuticals Inc grew revenues 76.23% from 1.04bn to 1.83bn while net income improved from a loss of 1.13bn to a smaller loss of 440.24m.
Gross margin | 87.00% |
---|---|
Net profit margin | -3.11% |
Operating margin | 4.38% |
Return on assets | -1.97% |
---|---|
Return on equity | -- |
Return on investment | -2.62% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Alnylam Pharmaceuticals Inc fell by 53.67m. Cash Flow from Financing totalled 172.13m or 9.41% of revenues. In addition the company generated 104.16m in cash from operations while cash used for investing totalled 336.35m.
Cash flow per share | -0.1382 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.024 |
---|---|
Tangible book value per share | -0.024 |
More ▼
Balance sheet in USDView more
Current ratio | 3.01 |
---|---|
Quick ratio | 2.93 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.00 |
More ▼